Nabriva Therapeutics PLC - ADR (NBRV) stock has fallen 21.54% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With NBRV Stock Today?
Nabriva Therapeutics PLC - ADR (NBRV) stock has risen 5.64% while the S&P 500 is down -0.33% as of 12:21 PM on Wednesday, Mar 3. NBRV is up $0.11 from the previous closing price of $1.93 on volume of 2,792,599 shares. Over the past year the S&P 500 is up 24.82% while NBRV is down -84.89%. NBRV lost -$7.59 per share in the over the last 12 months.
To screen for more stocks like Nabriva Therapeutics PLC - ADR click here.
More About Nabriva Therapeutics PLC - ADR
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections.
Click Here to get the full Stock Score Report on Nabriva Therapeutics PLC - ADR (NBRV) Stock.
